{"id":"cisplatin-based-induction-chemotherapy","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Nephrotoxicity"},{"rate":"10-30","effect":"Ototoxicity"},{"rate":"70-90","effect":"Nausea and vomiting"},{"rate":"25-30","effect":"Myelosuppression"},{"rate":"10-20","effect":"Peripheral neuropathy"},{"rate":"15-25","effect":"Electrolyte abnormalities (hypomagnesemia, hypokalemia)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cisplatin binds to DNA and forms intrastrand and interstrand crosslinks, which inhibit DNA synthesis and repair mechanisms, leading to apoptosis in rapidly dividing cancer cells. As an induction chemotherapy, it is typically administered before definitive treatment (such as surgery or radiation) to reduce tumor burden and improve treatment outcomes.","oneSentence":"Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing DNA replication and transcription in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:06:03.172Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Induction chemotherapy for locally advanced head and neck cancer"},{"name":"Induction chemotherapy for advanced ovarian cancer"},{"name":"Induction chemotherapy for advanced bladder cancer"},{"name":"Induction chemotherapy for other solid tumors"}]},"trialDetails":[{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT06792786","phase":"NA","title":"A Multicenter Prospective Study Evaluating Concurrent Chemoradiotherapy Following Induction Immunochemotherapy for Esophageal Cancer Based on Dynamic ctDNA Monitoring","status":"RECRUITING","sponsor":"The Central Hospital of Lishui City","startDate":"2024-12-10","conditions":"Esophageal Cancer, ctDNA","enrollment":30},{"nctId":"NCT07362979","phase":"PHASE2","title":"Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-12","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":243},{"nctId":"NCT02114229","phase":"PHASE2","title":"Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-05-14","conditions":"Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor","enrollment":125},{"nctId":"NCT07018622","phase":"PHASE2","title":"Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity","status":"RECRUITING","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2025-05-07","conditions":"Solid Tumors, Cisplatin Nephrotoxicity","enrollment":46},{"nctId":"NCT06239727","phase":"PHASE3","title":"Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-03-01","conditions":"Nasopharyngeal Carcinoma","enrollment":593},{"nctId":"NCT07446335","phase":"PHASE3","title":"A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2026-04","conditions":"Advanced Esophageal Squamous Cell Carcinoma","enrollment":578},{"nctId":"NCT04602533","phase":"PHASE2","title":"Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Michael Hopp","startDate":"2020-12-21","conditions":"Small Cell Lung Cancer Limited Stage","enrollment":105},{"nctId":"NCT06942039","phase":"EARLY_PHASE1","title":"Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation","status":"RECRUITING","sponsor":"C17 Council","startDate":"2025-09-23","conditions":"CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor","enrollment":15},{"nctId":"NCT07416058","phase":"PHASE2","title":"PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Association of Clinical Trials","startDate":"2026-01-31","conditions":"Lung Adenocarcinoma","enrollment":61},{"nctId":"NCT07082179","phase":"PHASE2","title":"A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2025-09-04","conditions":"NSCLC","enrollment":33},{"nctId":"NCT07381543","phase":"PHASE2","title":"Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-03","conditions":"Localized Small Cell Lung Cancer","enrollment":76},{"nctId":"NCT07214987","phase":"PHASE2","title":"PDT For Induction Therapy For Head And Neck Cancer","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-03-09","conditions":"Squamous Cell Carcinoma, Head and Neck Cancer Squamous Cell Carcinoma, Head and Neck Cancer","enrollment":26},{"nctId":"NCT05500092","phase":"PHASE2","title":"An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2023-01-25","conditions":"Resectable Stage IIA to IIIB Non-small Cell Lung Cancer","enrollment":17},{"nctId":"NCT05366166","phase":"PHASE2","title":"Pembrolizumab Plus Olaparib in LA-HNSCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2022-09-02","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":45},{"nctId":"NCT07218913","phase":"PHASE1","title":"Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-03-04","conditions":"Hearing Loss, Metastatic Malignant Germ Cell Tumor, Metastatic Malignant Nongerminomatous Germ Cell Tumor","enrollment":44},{"nctId":"NCT01175356","phase":"PHASE1","title":"Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2011-12-21","conditions":"Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma","enrollment":99},{"nctId":"NCT00336024","phase":"PHASE3","title":"Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-10-22","conditions":"Anaplastic Medulloblastoma, Medulloblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified","enrollment":91},{"nctId":"NCT07340515","phase":"PHASE3","title":"Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial","status":"RECRUITING","sponsor":"Man Hu","startDate":"2025-12-15","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":300},{"nctId":"NCT06155279","phase":"PHASE2","title":"Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istituto Oncologico Veneto IRCCS","startDate":"2024-11-06","conditions":"Pleural Mesothelioma","enrollment":41},{"nctId":"NCT07328854","phase":"PHASE3","title":"40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Ming-Yuan Chen","startDate":"2025-11-20","conditions":"Nasopharyngeal Carcinoma","enrollment":346},{"nctId":"NCT07328841","phase":"PHASE3","title":"Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy","status":"RECRUITING","sponsor":"Ming-Yuan Chen","startDate":"2025-11-18","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":456},{"nctId":"NCT05945823","phase":"PHASE2","title":"Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2023-07-13","conditions":"Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer","enrollment":53},{"nctId":"NCT04765709","phase":"PHASE2","title":"Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC","status":"TERMINATED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-09-24","conditions":"Non-small Cell Lung Cancer Stage III","enrollment":10},{"nctId":"NCT06281964","phase":"PHASE3","title":"Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.","status":"ENROLLING_BY_INVITATION","sponsor":"Avistone Biotechnology Co., Ltd.","startDate":"2023-12-01","conditions":"Non-Small-Cell Lung Cancer","enrollment":327},{"nctId":"NCT04745689","phase":"PHASE2","title":"Study of AZD2811 + Durvalumab in ES-SCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-02-23","conditions":"Small-Cell Lung Cancer","enrollment":31},{"nctId":"NCT06846450","phase":"PHASE3","title":"Phase 3 Trial Comparing IMRT or IMPT Plus CIRT for Patients With NPC","status":"RECRUITING","sponsor":"Lin Kong, MD","startDate":"2025-04-01","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":470},{"nctId":"NCT07252375","phase":"PHASE2","title":"A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-11-30","conditions":"Nasopharyngeal Carcinoma (NPC), CTIT-Chemotherapy Induced Thrombocytopenia","enrollment":35},{"nctId":"NCT07248696","phase":"NA","title":"Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chongqing University Cancer Hospital","startDate":"2025-10-04","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":32},{"nctId":"NCT01857934","phase":"PHASE2","title":"Therapy for Children With Advanced Stage Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-07-05","conditions":"Neuroblastoma","enrollment":153},{"nctId":"NCT06008093","phase":"PHASE3","title":"A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-04-04","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":280},{"nctId":"NCT03520686","phase":"PHASE3","title":"Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-18","conditions":"Non Small Cell Lung Cancer","enrollment":1538},{"nctId":"NCT03786783","phase":"PHASE2","title":"Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-03-04","conditions":"Ganglioneuroblastoma, High Risk Neuroblastoma","enrollment":42},{"nctId":"NCT06196853","phase":"PHASE2, PHASE3","title":"Prevention of Cisplatin-induced Nephrotoxicity","status":"NOT_YET_RECRUITING","sponsor":"Mahidol University","startDate":"2025-12-01","conditions":"Acute Kidney Injury, Renal Tubulopathy","enrollment":24},{"nctId":"NCT04722523","phase":"PHASE1","title":"A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-01-20","conditions":"Head and Neck Cancer, Head Cancer, Head Cancer Neck","enrollment":40},{"nctId":"NCT04547504","phase":"PHASE3","title":"PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Brest","startDate":"2020-12-22","conditions":"Non-small-cell Lung Cancer","enrollment":349},{"nctId":"NCT07177443","phase":"PHASE3","title":"Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-09-25","conditions":"Locally Advanced Nasopharyngeal Carcinoma","enrollment":456},{"nctId":"NCT05014815","phase":"PHASE2","title":"Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"BeiGene","startDate":"2021-11-16","conditions":"Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV","enrollment":272},{"nctId":"NCT04887831","phase":"PHASE2","title":"Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab","status":"TERMINATED","sponsor":"G1 Therapeutics, Inc.","startDate":"2021-06-04","conditions":"Urothelial Carcinoma, Bladder Cancer, Myelosuppression Adult","enrollment":92},{"nctId":"NCT07155044","phase":"","title":"A Comparative Study of Neoadjuvant Chemotherapy Versus Upfront Radical Surgery for Upper Tract Urothelial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Changhai Hospital","startDate":"2024-05-15","conditions":"UTUC, UC (Urothelial Cancer)","enrollment":120},{"nctId":"NCT07108777","phase":"PHASE2","title":"L-Carnitine Protective Effect in Nephrotoxicity","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-08-10","conditions":"Nephrotoxicity","enrollment":46},{"nctId":"NCT06091943","phase":"PHASE1","title":"Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2023-11-16","conditions":"Non-small Cell Lung Cancer","enrollment":62},{"nctId":"NCT07095998","phase":"NA","title":"Nerve Excitability in Cisplatin-Induced Peripheral Neuropathy","status":"NOT_YET_RECRUITING","sponsor":"Ka-Wai Ho","startDate":"2025-08","conditions":"Peripheral Neuropathy Due to Chemotherapy, Peripheral Neuropathy, Neurotoxicity Syndromes","enrollment":60},{"nctId":"NCT07092696","phase":"PHASE2","title":"Induction Immunotherapy Combined With Chemotherapy Followed by Concurrent Chemoradiotherap and Immunotherapy for Cervical Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-12-01","conditions":"Cervical Cancer","enrollment":34},{"nctId":"NCT07083375","phase":"PHASE2","title":"A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Zhijie Wang","startDate":"2025-08-01","conditions":"Extensive Small Cell Lung Cancer","enrollment":56},{"nctId":"NCT05628233","phase":"PHASE2","title":"SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic Disease","status":"COMPLETED","sponsor":"Sensorion","startDate":"2022-12-30","conditions":"Hearing Loss Ototoxic","enrollment":48},{"nctId":"NCT05312671","phase":"PHASE2","title":"Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2022-06-27","conditions":"Small Cell Neuroendocrine Carcinoma of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder","enrollment":63},{"nctId":"NCT04221035","phase":"PHASE3","title":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2019-11-05","conditions":"High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy","enrollment":800},{"nctId":"NCT03387774","phase":"PHASE3","title":"Efficacy of Ulinastatin for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2018-01-30","conditions":"Oral Mucositis (Ulcerative) Due to Radiation","enrollment":179},{"nctId":"NCT06957938","phase":"PHASE3","title":"Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-04-28","conditions":"Laryngeal Carcinoma, Hypopharyngeal Carcinoma","enrollment":168},{"nctId":"NCT03107182","phase":"PHASE2","title":"Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2017-06-27","conditions":"HPV-Related Squamous Cell Carcinoma, HNSCC","enrollment":72},{"nctId":"NCT06933394","phase":"PHASE2","title":"Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-05-01","conditions":"Neuroblastoma","enrollment":92},{"nctId":"NCT06140966","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2023-10-20","conditions":"Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma","enrollment":54},{"nctId":"NCT05508347","phase":"PHASE2","title":"Nituzumab (Taixinsheng ®） A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2022-04-20","conditions":"Nasopharyngeal Carcinoma","enrollment":170},{"nctId":"NCT05012254","phase":"PHASE2","title":"Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación GECP","startDate":"2021-11-18","conditions":"Non Small Cell Lung Cancer, Brain Metastases, Adult, Lung Cancer","enrollment":71},{"nctId":"NCT05255302","phase":"PHASE2, PHASE3","title":"De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction","status":"RECRUITING","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2022-05-02","conditions":"Metastatic NSCLC","enrollment":1360},{"nctId":"NCT05304468","phase":"PHASE3","title":"Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-05-11","conditions":"Nasopharyngeal Carcinoma","enrollment":452},{"nctId":"NCT06494943","phase":"PHASE1, PHASE2","title":"Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-06-26","conditions":"Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma","enrollment":27},{"nctId":"NCT06686381","phase":"PHASE2","title":"Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo/Immunotherapy+ Radiation Therapy+ Maintenance Immunotherapy vs. W&W","status":"NOT_YET_RECRUITING","sponsor":"American University of Beirut Medical Center","startDate":"2025-04-15","conditions":"Muscle-invasive Bladder Cancer","enrollment":80},{"nctId":"NCT03404791","phase":"PHASE1","title":"A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-11-20","conditions":"Urinary Bladder Neoplasms","enrollment":35},{"nctId":"NCT01828099","phase":"PHASE3","title":"LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-07-09","conditions":"Non-Small Cell Lung Cancer","enrollment":376},{"nctId":"NCT00554788","phase":"PHASE3","title":"Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2008-05-06","conditions":"Extraocular Retinoblastoma","enrollment":60},{"nctId":"NCT04364048","phase":"PHASE2","title":"Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Rachel Sanborn","startDate":"2020-06-18","conditions":"Lung Cancer, Non-small Cell Carcinoma","enrollment":10},{"nctId":"NCT06697613","phase":"","title":"Development and Validation of a Prediction Model for AKI Following Cisplatin-Based HIPEC in Patients With Ovarian Cancer","status":"COMPLETED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2016-01-01","conditions":"Ovarian Cancer, AKI - Acute Kidney Injury","enrollment":150},{"nctId":"NCT06675214","phase":"PHASE3","title":"Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-07-30","conditions":"Nasopharyngeal Carcinoma, De-escalation Therapy","enrollment":586},{"nctId":"NCT04428333","phase":"PHASE3","title":"Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2020-08-12","conditions":"Neoplasms, Head and Neck","enrollment":117},{"nctId":"NCT02258659","phase":"PHASE2","title":"Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2014-09-22","conditions":"Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx","enrollment":62},{"nctId":"NCT02129699","phase":"PHASE3","title":"Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy","status":"TERMINATED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2015-01-06","conditions":"Lung Cancer Non-small Cell Stage IV","enrollment":595},{"nctId":"NCT06510660","phase":"PHASE2","title":"Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2024-04-11","conditions":"Esophageal Squamous Cell Carcinoma, Immunotherapy, Biomarkers","enrollment":48},{"nctId":"NCT06554535","phase":"PHASE2","title":"Efficacy and Safety of Serplulimab With Chemotherapy and Aspirin in Untreated Extensive-Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2024-10-01","conditions":"Extensive-Stage Small Cell Lung Cancer, Treatment-naïve for Systemic Therapy Targeting Extensive-Stage Small Cell Lung Cancer, ECOG Performance Status Score of 0 or 1","enrollment":43},{"nctId":"NCT06554028","phase":"PHASE2","title":"Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-08","conditions":"Laryngeal Cancer, Hypopharynx Cancer, Laryngeal Neoplasms","enrollment":46},{"nctId":"NCT03387111","phase":"PHASE1, PHASE2","title":"QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2018-01-09","conditions":"Squamous Cell Carcinoma","enrollment":4},{"nctId":"NCT01798004","phase":"PHASE1","title":"Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2013-04-09","conditions":"Ganglioneuroblastoma, Stage 1 Neuroblastoma, Stage 2 Neuroblastoma","enrollment":150},{"nctId":"NCT06491082","phase":"","title":"Chemotherapy Induced Neuropathy in Cancer Patients","status":"RECRUITING","sponsor":"Swami Rama Himalayan University","startDate":"2022-11-23","conditions":"Chemotherapy-induced Peripheral Neuropathy","enrollment":124},{"nctId":"NCT06472570","phase":"NA","title":"Stereotactic Radiosurgery in Patients With Head and Neck Region Tumours","status":"RECRUITING","sponsor":"Maria Sklodowska-Curie National Research Institute of Oncology","startDate":"2019-10-26","conditions":"Head and Neck Cancer","enrollment":80},{"nctId":"NCT05966233","phase":"PHASE2","title":"R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma","status":"WITHDRAWN","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2024-01","conditions":"Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent","enrollment":""},{"nctId":"NCT05397262","phase":"NA","title":"Organ-preservative Therapy of Bladder Cancer With Radiotherapy or Radiochemotherapy Combined With Hyperthermia","status":"RECRUITING","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2017-03-29","conditions":"Bladder Cancer","enrollment":1000},{"nctId":"NCT06378892","phase":"PHASE2","title":"A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib","status":"RECRUITING","sponsor":"Centro di Riferimento Oncologico - Aviano","startDate":"2024-03-15","conditions":"Non Small Cell Lung Cancer Metastatic, ALK Gene Mutation","enrollment":45},{"nctId":"NCT00653068","phase":"PHASE3","title":"Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2009-02-10","conditions":"Childhood Atypical Teratoid/Rhabdoid Tumor","enrollment":70},{"nctId":"NCT06231680","phase":"PHASE2","title":"Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2024-01-19","conditions":"Lung Cancer, Nonsmall Cell, Esophageal Carcinoma","enrollment":132},{"nctId":"NCT06282211","phase":"PHASE3","title":"the Efficacy and Safety of Ondansetron Oral Soluble Pellicles","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Xinxiang Medical College","startDate":"2024-02-20","conditions":"Nausea and Vomiting","enrollment":184},{"nctId":"NCT06255210","phase":"PHASE2","title":"Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON)","status":"RECRUITING","sponsor":"Hongmeng Yu","startDate":"2024-03-01","conditions":"Olfactory Neuroblastoma","enrollment":25},{"nctId":"NCT05492123","phase":"PHASE2","title":"Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer","status":"RECRUITING","sponsor":"Hospital Israelita Albert Einstein","startDate":"2022-08-30","conditions":"Uterine Cervical Neoplasms","enrollment":112},{"nctId":"NCT03894891","phase":"PHASE2","title":"Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2019-06-11","conditions":"Head and Neck Cancer","enrollment":6},{"nctId":"NCT06092957","phase":"PHASE3","title":"Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-10-09","conditions":"Nasopharyngeal Carcinoma, De-escalation Therapy","enrollment":504},{"nctId":"NCT06156891","phase":"PHASE2","title":"PD-1 Inhibitor Based Induction Chemotherapy Followed by De-escalation Protocols in OPSCC","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-06-29","conditions":"Oropharyngeal Cancer","enrollment":60},{"nctId":"NCT02290145","phase":"PHASE2","title":"Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2016-12","conditions":"Mouth Neoplasms, Carcinoma, Squamous Cell","enrollment":48},{"nctId":"NCT06140082","phase":"","title":"Study on the Association of GSTP1 and Other Gene Polymorphisms With Platinum-induced Myelosuppression","status":"UNKNOWN","sponsor":"LI YAN","startDate":"2023-12-01","conditions":"Non-small Cell Lung Cancer","enrollment":477},{"nctId":"NCT05792228","phase":"NA","title":"A Standardized Intervention to Improve the Management of Chemotherapy-induced Nausea and Vomiting","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-04-02","conditions":"Squamous Cell Carcinoma of Head and Neck, Chemotherapy Induced Nausea and Vomiting","enrollment":92},{"nctId":"NCT04277858","phase":"PHASE2","title":"Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Oropharyngeal Cancer.","status":"RECRUITING","sponsor":"Nader Sadeghi","startDate":"2018-08-14","conditions":"Oropharynx Cancer, Tonsil Cancer, Throat Cancer","enrollment":60},{"nctId":"NCT05161533","phase":"PHASE2","title":"Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial","status":"WITHDRAWN","sponsor":"University of Washington","startDate":"2023-10-19","conditions":"Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8","enrollment":""},{"nctId":"NCT05174832","phase":"PHASE2","title":"Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-09-07","conditions":"Triple Negative Breast Cancer","enrollment":136},{"nctId":"NCT06039631","phase":"PHASE2","title":"Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-08-22","conditions":"Larynx Cancer, Hypopharyngeal Cancer","enrollment":82},{"nctId":"NCT06031597","phase":"PHASE3","title":"Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2023-09-15","conditions":"Non-small Cell Lung Cancer Stage III","enrollment":105},{"nctId":"NCT06019520","phase":"NA","title":"Role of N-Acetylcysteine for Prevention of Cisplatin-induced Nephrotoxicity","status":"UNKNOWN","sponsor":"Foundation University Islamabad","startDate":"2023-08-09","conditions":"Drug Toxicity","enrollment":70},{"nctId":"NCT04522050","phase":"PHASE1","title":"Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Fifth Affiliated Hospital, Sun Yat-Sen University","startDate":"2018-10-01","conditions":"Nasopharyngeal Carcinoma","enrollment":65},{"nctId":"NCT01084083","phase":"PHASE2","title":"Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2010-08-11","conditions":"Head and Neck Cancer, Precancerous Condition","enrollment":90},{"nctId":"NCT03919552","phase":"PHASE3","title":"Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2018-01-31","conditions":"Cisplatin, Carboplatin, NPC","enrollment":482},{"nctId":"NCT05872880","phase":"","title":"TPExtreme Induced Chemotherapy Followed by Surgery and Radiotherapy in the Oral Carcinoma.","status":"RECRUITING","sponsor":"Xiangya Hospital of Central South University","startDate":"2022-04-01","conditions":"Oral Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma","enrollment":124},{"nctId":"NCT05129748","phase":"PHASE2","title":"Efficacy of Sodium Thiosulfate and Mannitol in Reducing Ototoxicity in Adult Patients Receiving Cisplatin Chemotherapy","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2023-02-15","conditions":"Ototoxic Hearing Loss","enrollment":92}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":58,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Cisplatin-based induction chemotherapy","genericName":"Cisplatin-based induction chemotherapy","companyName":"Ming-Yuan Chen","companyId":"ming-yuan-chen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing DNA replication and transcription in cancer cells. Used for Induction chemotherapy for locally advanced head and neck cancer, Induction chemotherapy for advanced ovarian cancer, Induction chemotherapy for advanced bladder cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}